What Is Tirzepatide? Research Overview

Tirzepatide is a synthetic dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist studied in metabolic and incretin research. Bolt Peptide supplies only a research-use-only reference compound for controlled in-vitro laboratory work by qualified professionals. It is not a finished pharmaceutical product and is not for human or veterinary use.

Quick facts

• Class: dual GIP and GLP-1 receptor agonist (incretin-mimetic peptide)
• Research focus: metabolic, incretin-signaling, and endocrine research
• Form: lyophilized powder for laboratory research use only
• Status: research use only — not for human or veterinary use

What is Tirzepatide?

Tirzepatide (research code LY3298176) is a single-chain synthetic peptide engineered to engage two incretin receptors at once: the GIP receptor and the GLP-1 receptor. Native incretin hormones — GIP and GLP-1 — are released by the gut and participate in the regulation of glucose-dependent insulin signaling. Tirzepatide was designed as a unimolecular agonist that activates both receptor pathways with a single molecule, which distinguishes it from selective GLP-1 receptor agonists that target only one pathway. As a research reference compound, it is used in laboratory and preclinical settings to study incretin receptor biology and dual-agonist signaling.

What does the research show?

In published pharmacology research, tirzepatide has been characterized as an “imbalanced” and “biased” dual agonist: it engages the GIP receptor comparably to native GIP while showing biased signaling at the GLP-1 receptor that favors cAMP generation over β-arrestin recruitment [1]. This receptor-level profile has been studied as a possible explanation for how dual agonism differs mechanistically from single GLP-1 receptor activation.

In clinical research, tirzepatide has been evaluated in large randomized trials. The SURPASS-2 trial studied once-weekly tirzepatide compared with semaglutide in adults with type 2 diabetes [2], and the SURMOUNT-1 trial studied once-weekly tirzepatide in adults with obesity [3]. These trials are reported here only to describe the published research record for the molecule; they do not describe this research-use-only material, and nothing here should be read as a benefit claim for any reader.

Mechanisms studied in the lab

• GIP receptor agonism — activation of the GIP receptor and downstream incretin signaling.
• GLP-1 receptor agonism — activation of the GLP-1 receptor, with biased cAMP-favoring signaling reported in vitro.
• Dual incretin signaling — combined engagement of both receptor pathways by a single molecule, a focus of structural and signaling studies.

Research status and safety

This tirzepatide reference material is supplied strictly for in-vitro laboratory and analytical research by qualified personnel. It is not for human or veterinary use or consumption and must be handled under applicable institutional protocols and laboratory safety procedures.

Handling

Tirzepatide reference material is provided in lyophilized form. Qualified personnel must determine solvent compatibility, material handling, and final analytical concentration under an approved protocol and institutional SOP. See the laboratory concentration and handling reference, browse related GLP research materials, or review Tirzepatide product details.

FAQ

How is tirzepatide different from semaglutide?
In published research, semaglutide is a selective GLP-1 receptor agonist, whereas tirzepatide is a dual agonist that engages both the GIP and GLP-1 receptors with a single molecule. This dual-receptor mechanism is the primary structural and pharmacological difference studied in the literature. Read about semaglutide.

What does “dual GIP/GLP-1 receptor agonist” mean?
It means the molecule binds and activates two different incretin receptors — the GIP receptor and the GLP-1 receptor — rather than just one.

Is this a finished commercial product?
No. Bolt Peptide supplies a research-use-only reference material for controlled laboratory study. It is not a pharmaceutical product and is not for human use.

References

1. Willard FS, Douros JD, Gabe MBN, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. PMC7526454
2. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503–515. PubMed 34170647
3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. PubMed 35658024

For research use only. Not for human or veterinary use. Statements have not been evaluated by the FDA.